

Reaccumulation rate of Pleural Effusions After Therapeutic Aspiration: An observational cohort study to determine baseline factors associated with rate of pleural fluid reaccumulation following therapeutic aspiration in patients with malignant pleural effusion attending a pleural clinic

Internal Reference Number / Short title: REPEAT

Ethics Ref: TBC

IRAS Project ID: 295614

Date and Version No: 05May2021, Version 1.0

Chief Investigator:

Dr Eleanor Mishra

Norfolk and Norwich University Hospitals NHS Foundation Trust

University of East Anglia

eleanor.mishra@nnuh.nhs.uk

Investigators:

Professor Najib Rahman, University of Oxford

Dr Allan Clark, University of East Anglia

Professor Nick Maskell, University of Bristol


Dr John Corcoran, University Hospitals Plymouth NHS Foundation Trust

Dr Rakesh Panchal, University Hospitals of Leicester NHS Trust

Sponsor:

Norfolk and Norwich University Hospitals NHS Foundation Trust

Chief Investigator Signature:



The Investigators have no conflicts of interest to declare.

Confidentiality Statement

This document contains confidential information that must not be disclosed to anyone other than the Sponsor, the Investigator Team, HRA, host organisation, and members of the Research Ethics Committee, unless authorised to do so.



Trial Title: Reaccumulation rate of Pleural Effusions After Therapeutic Aspiration: An observational cohort study to determine baseline factors associated with rate of pleural fluid reaccumulation following therapeutic aspiration in patients with pleural effusion attending a pleural clinic

Protocol Date and Version No: 15Apr2021, Version 1.0

Protocol signature page

The undersigned has read and understood the trial protocol detailed above and agrees to conduct the trial in compliance with the protocol.

Principal Investigator

(Please print name)

Signature

Site name

Date



TABLE OF CONTENTS

1.	KEY CONTACTS.....	6
2.	LAY SUMMARY.....	7
3.	ABBREVIATIONS.....	8
4.	BACKGROUND AND RATIONALE.....	10
5.	OBJECTIVES AND OUTCOME MEASURES.....	12
6.	STUDY DESIGN	14
7.	PARTICIPANT IDENTIFICATION	14
7.1.	Study Participants.....	14
7.2.	Inclusion Criteria.....	14
7.3.	Exclusion Criteria	15
8.	PROTOCOL PROCEDURES	15
8.1.	Recruitment.....	15
8.1.	Screening and Eligibility Assessment.....	15
8.1.	Informed Consent.....	15
8.2.	Baseline Assessments.....	16
8.3.	Follow up visits	16
8.4.	Sample Handling.....	17
8.5.	Discontinuation/Withdrawal of Participants from Study.....	17
8.6.	Definition of End of Study	18
9.	DISTRESS PROTOCOL	18
10.	STATISTICS AND DATA ANALYSIS.....	18
10.1.	Description of Statistical Methods	18



10.2.	Sample size and analysis plan.....	18
10.3.	Procedure for Accounting for Missing, Unused, and Spurious Data.	19
10.4.	Inclusion in Analysis.....	19
10.5.	Assessment of effusion size on chest X-ray.....	20
11.	DATA MANAGEMENT	20
11.1.	Source Data	20
11.2.	Access to Data	20
11.3.	Data Recording and Record Keeping	20
12.	QUALITY ASSURANCE PROCEDURES	21
13.	ETHICAL AND REGULATORY CONSIDERATIONS.....	21
13.1.	Declaration of Helsinki.....	21
13.2.	Guidelines for Good Clinical Practice	21
13.3.	Approvals.....	21
13.4.	Reporting	21
13.5.	Participant Confidentiality.....	21
13.6.	Expenses and Benefits.....	22
14.	CORONAVIRUS-19 RISK MITIGATION	22
15.	FINANCE AND INSURANCE	22
15.1.	Funding	22
15.2.	Insurance	22
16.	PUBLICATION POLICY.....	23
17.	APPENDIX 1: Study Flow chart.....	23
18.	REFERENCES	24



1. KEY CONTACTS

Chief Investigator	<p>Dr Eleanor Mishra</p> <p>Norfolk and Norwich University Hospitals NHS Foundation Trust</p> <p>University of East Anglia</p> <p>01603 286286</p> <p>eleanor.mishra@nnuh.nhs.uk</p>
Sponsor	<p>Norfolk and Norwich University Hospitals NHS Foundation Trust</p> <p>Colney Lane, Norwich, Norfolk</p> <p>01603 286 286</p>
Funder	National Institute for Health Research – Research for Patient Benefit
Clinical Trials Unit	<p>Oxford Respiratory Trials Unit</p> <p>University of Oxford</p> <p>Churchill Hospital</p> <p>Oxford</p>
Trial Manager	<p>Magda Laskawiec-Szkonter</p> <p>Oxford Respiratory Trials Unit</p> <p>Magda.laskawiec@ouh.nhs.uk</p>
Statistician	<p>Dr Allan Clark</p> <p>University of East Anglia</p> <p>allan.clark@uea.ac.uk</p>



2. LAY SUMMARY

People with incurable cancer commonly feel breathless due to build up of fluid around the lung. Aims of treatment are to help symptoms and prevent admission to hospital. We do this by draining fluid off, but it often comes back. When this happens, we offer the patient a permanent implanted drain, so they can drain the fluid off regularly at home. However, sometimes the fluid builds up very quickly, before we have time to implant a drain. The patient becomes very breathless and needs an emergency hospital admission. In other people, the fluid builds up slowly and they may never need another drain.

The aim of this study is to improve treatment by finding a way to predict how quickly fluid will come back. It will be run in 5 hospitals across England and involve 240 patients over 3 years. When patients first come to have fluid drained, we will record information about them and their disease. We will measure how quickly the fluid comes back by comparing their chest X-ray after draining the fluid with their chest X-ray a week later. We will record hospital admissions and need for fluid drainage over the following 3 months. We will use this information to create a clinical score which can predict how quickly fluid will come back. We will then test this score in a second group of patients to make sure it works. The study is designed so that people don't have to make extra hospital visits or have extra tests, which means there are no disadvantages for people who get involved. We have already tested this trial design in 20 patients to show we can do it.

The idea for this study came from one of our patients who had just had fluid drained and asked, 'when will it come back?' We couldn't answer his question and therefore developed this study to answer it for other patients in the future. Our patients, including those involved in testing the trial design, and members of the public have been involved in the design of this study and will continue to be involved to ensure that it will improve their treatment.

This score will be used to inform patients so they can choose the best treatment for them. If we know the fluid will build up quickly, we can offer patients a permanent drain straight away. This will control their breathlessness better and prevent them coming into hospital. On the other hand, if patients know their fluid will build up slowly, they may choose simply to have the fluid drained when needed without a permanent drain.



3. ABBREVIATIONS

7-DVQ	7 day visual analogue scale for dyspnoea questionnaire
BNP	Brain natriuretic protein
CI	Chief Investigator
CRF	Case Report Form
CT	Computer Tomography
CXR	Chest radiograph
ECOG PS	Eastern Co-operative Oncology Group Performance Status
GCP	Good Clinical Practice
HRA	Health Research Authority
IB	Investigators Brochure
ICH	International Conference of Harmonisation
ICF	Informed Consent Form
LDH	Lactate dehydrogenase
NHS	National Health Service
NRES	National Research Ethics Service
PF	Pleural fluid
PI	Principal Investigator
PIL	Patient Information Leaflet
PMC	Pleural mesothelial cells
R&D	NHS Trust R&D Department
REC	Research Ethics Committee
SDV	Source Data Verification
SOP	Standard Operating Procedure



TMF	Trial Master File
TP	Total protein
US	Ultrasound
VASD	Visual analogue scale for dyspnoea
VEGF	Vascular endothelial growth factor



4. BACKGROUND AND RATIONALE

Patients with cancer develop malignant pleural effusions (MPEs) when fluid collects between the lung and chest wall (the pleural space). MPEs are common, with more than 30,000 new cases per year in the United Kingdom. They are caused by cancers which have spread to the lining of the pleural space, and are common in breast and lung cancer and mesothelioma, a type of cancer caused by exposure to asbestos¹. MPE may be the first presentation of cancer or develop in a patient with known cancer, but sadly always means the disease is not curable. Patients experience breathlessness, chest discomfort and cough².

Development of a pleural effusion occurs due to excess production of pleural fluid. The pleural space is lined by a single layer of pleural mesothelial cells (PMCs). These regulate production of pleural fluid through control of substances passing in between mesothelial cells (via tight junctions) and through cells³. Cancer cells in the pleural space stimulate production of a pleural effusion via inflammatory pathways and release of vasoactive mediators, such as vascular endothelial growth factor (VEGF)⁴. This increases mesothelial permeability via loosening of tight junctions between PMCs, allowing passage of proteins and fluid into the pleural space. VEGF levels are raised in MPEs⁵. However, the mechanisms are complex and not yet fully understood.

Treatment of MPE aims to effectively relieve symptoms, prevent emergency hospital admission and reduce the number of procedures and cancelled procedures. Patients usually attend a specialist Pleural Clinic as an outpatient for an initial drainage procedure (therapeutic aspiration). This is an effective, simple and quick way of treating symptoms. However, this does not treat the underlying cause of fluid accumulation. Pleural fluid usually comes back, which results in more breathlessness. When this happens, a definitive procedure (chest drain and pleurodesis or indwelling pleural catheter insertion) is performed⁶.

Our pilot data demonstrates that the fluid comes back at a very variable rate. Some patients produce pleural fluid quickly and develop rapid onset, severe breathlessness, which results in an emergency hospital attendance. In contrast, some effusions develop more slowly, and patients may attend for a planned drainage procedure which has to be cancelled due to lack of fluid or have an unnecessary procedure. Currently, there is no way to predict the rate of fluid recurrence for each individual patient.

In summary, MPEs are a common cause of breathlessness in patients with advanced cancer. There is wide variation in rate of fluid accumulation. Rapid accumulation can result in an emergency hospital admission whereas slow accumulation can lead to unnecessary or cancelled procedures.

Why is this research important in terms of improving the health of the patients and improving health care services?

This research is important to improve the care offered to patients with MPEs. As part of the pilot work for this study, we surveyed pleural clinicians involved in deciding when patients undergo a definitive pleural procedure for MPE. Over half (58%) reported that their patients often or sometimes get admitted as an emergency with severe breathlessness caused by recurrent MPE. Over one quarter of cancer patients admitted as an emergency die in hospital⁷. Patients do not want hospital admissions, find them tiring and experience unnecessary delays^{8,9}. The results of this research will enable us to identify patients with rapid



pleural fluid accumulation so they can undergo an early definitive pleural procedure and prevent emergency hospital admissions.

This research will also identify patients whose MPE will reaccumulate slowly or not at all. These patients may currently undergo unnecessary definitive pleural procedures or have their procedure cancelled due to lack of pleural fluid. Our survey data demonstrated that 45% of pleural clinicians often or sometimes cancel a pleural procedure due to lack of fluid. This is inconvenient and distressing for the patient.

Our research will also help clinicians plan pleural services, by identifying which patients require an urgent procedure and reducing unnecessary and cancelled procedures. Our survey revealed that 94% of pleural clinicians thought a score that enabled them to predict how quickly MPEs would recur would help plan their service.

Review of existing evidence

There has been little research to date studying predictors of pleural fluid reaccumulation. One previous retrospective cohort study found that size of effusion on chest X-ray prior to therapeutic aspiration, volume of pleural fluid drained during therapeutic aspiration, pleural fluid lactate dehydrogenase (LDH) levels and positive pleural fluid cytology predicted a further pleural drainage procedure being carried out in a single centre with a highly protocol-led pathway¹⁰. However, these variables were not predictive in other centres. This paper demonstrated wide variation in time to a further drainage procedure, with 30% of patients requiring a further procedure within 15 days whereas 52% had not had another procedure at 90 days. Boshuizen et al. also found that volume of pleural fluid drained was predictive of need for a further pleural intervention¹¹.

Despite the lack of evidence for predictors of pleural fluid recurrence, our survey demonstrated that 71% of clinicians try to predict how quickly pleural fluid will recur. However, there was no consistent method for doing this. Clinicians based this judgement on variables such as speed of onset of symptoms, initial size of the effusion, tumour type and previous recurrence rate (based on review of previous radiology/time between previous drainages).

Data from feasibility study

We successfully recruited 20 patients to a feasibility study at the Norfolk and Norwich Pleural Unit from January to July 2019. We screened 40 patients attending the Pleural Clinic for a therapeutic aspiration of their effusion for eligibility and identified 23 eligible patients. Of these, 20 consented to enrolment. All enrolled patients attended the 1 week primary outcome follow up. The feasibility study included qualitative interviewing of the patients and patients were asked about their experience of the study as part of this interviewing. Our results demonstrate that this study is acceptable to patients and recruitment to target is feasible.

The feasibility study identified that only 15 of these 20 patients subsequently underwent therapeutic aspiration. This was because thoracic ultrasound performed following enrolment demonstrated that there was insufficient fluid for a therapeutic aspiration or that the fluid was not amenable to drainage. Therefore, we altered the inclusion criteria to specify that patients must have an



effusion demonstrated on thoracic ultrasound or computer tomography (CT) scan prior to enrolment. This change to the inclusion criteria will ensure all enrolled patients will undergo therapeutic aspiration.

We plan to analyse data only on patients with a final diagnosis of a malignant pleural effusion because effusions from other causes usually resolve with treatment of the underlying cause and recurrence is not a problem. However, when patients attend for therapeutic aspiration, the final diagnosis may not be known. Of the 15 patients who underwent therapeutic aspiration in our feasibility study, 12 of them had a final diagnosis of malignancy. For the full study, we plan to recruit 200 patients in Phase 1 to include at least 150 with a final diagnosis of MPE and full primary outcome data.

5. OBJECTIVES AND OUTCOME MEASURES

Objectives	Outcome Measures	Timepoint(s) of evaluation of this outcome measure (if applicable)
Primary Objective: To identify candidate biomarkers associated with rate of pleural fluid accumulation in patients with MPE and to use these biomarkers to develop and validate a clinical score to predict rate of reaccumulation;	Patient biomarkers Effusion biomarkers Pleural fluid biomarkers Serum biomarkers (see section 5.1 for complete list of biomarkers) Rate of pleural fluid accumulation based on increase in size of pleural effusion ¹²	Day 0 CXR immediately post aspiration and at day 7

5.1. Complete list of candidate biomarkers to be assessed for the primary objective

The candidate biomarkers are:

- Patient biomarkers:
 - Duration of symptoms;
 - Type of malignancy;
 - Known malignancy or first presentation;
 - Severity of pre-procedure breathlessness (measured on visual analogue scale);
 - Previous chemotherapy and/or radiotherapy and/or immunotherapy;
 - Current chemotherapy and/or radiotherapy and/or immunotherapy;



- Current use of diuretics;
- Emergency (via A&E or acute medical unit) or urgent presentation (via GP or oncology);
- Performance status (assessed using Eastern Co-operative Group scale);
- Co-morbidities (chronic renal failure, liver disease, cardiac failure).
- Effusion biomarkers:
 - Size of effusion on pre-procedure chest X-ray (measured as percentage opacification of hemithorax). This is a validated measure of effusion size.
 - Size of effusion on pre-procedure ultrasound (measured from hemidiaphragm to top of effusion);
 - Side of effusion;
 - Volume of fluid drained during therapeutic aspiration (ml);
 - Degree of pleural fluid septations (categorised as none, mild, moderate or severe) on ultrasound;
 - Significant non-expandable lung on post-procedure chest X-ray;
 - Pleural pressures measured by manometry (substudy in 20 patients only in Norwich).
- Pleural fluid biomarkers:
 - Total protein;
 - pH;
 - Glucose;
 - Lactose dehydrogenase (LDH);
 - Cytology (categorised as positive i.e. malignant cells present or negative)
- Serum biomarkers:
 - Haemoglobin;
 - White cell count, including neutrophil and leukocyte subsets;
 - C reactive protein;
 - Total protein;
 - Estimated glomerular filtration rate (eGFR);
 - LDH;
 - N-terminal pro-brain natriuretic peptide (NT-proBNP)

Why were these biomarkers chosen?

Duration of symptoms, underlying diagnosis and pre-procedure breathlessness were common factors identified by our clinician survey as being important in estimating how quickly pleural fluid will recur. Current treatment may reduce how quickly an effusion recurs. The co-morbidities specified are all associated with production of pleural fluid which may increase rate of reaccumulation (despite the main cause being malignancy). Pre-procedure size of effusion was identified on two previous retrospective cohort studies as being associated with need for a further pleural procedure, and we are measuring this in three ways (on X-ray, ultrasound and volume fluid drained). Septations are fibrin or collagen walls which develop within the effusion and impair drainage, and therefore may influence rate of reaccumulation. Non-expandable lung is defined as failure of the lung to re-expand following therapeutic aspiration and will be visible on the post-procedure chest X-ray. It is associated with significant negative pressure within the pleural space, which may drive rapid pleural fluid reaccumulation. pH, LDH and cytology have been identified in previous studies as being associated with need for a further pleural procedure. Total protein determines whether an effusion is an exudate or transudate and therefore is an important variable determining the mechanism of pleural fluid production. LDH has been identified as a variable associated



with poor prognosis in patients with MPE. Haemoglobin, neutrophil:leukocyte ratio and C reactive protein have been shown to be associated with prognosis in patients with MPE. NT-proBNP is a measure of cardiac function and eGFR is a measure of renal function, so these variables may affect pleural fluid reaccumulation. High pleural fluid pressures may be associated with a strong drive to produce pleural fluid and hence rapid reaccumulation. These candidate biomarkers will be assessed to see which are appropriate for further analysis, based on our ability to detect variability within these measurements. If required, principal component analysis will be used to reduce the number of variables to eight for further analysis.

6. STUDY DESIGN

This will be an observational cohort study recruiting patients with a pleural effusion attending the pleural clinic at 5 UK hospitals for a therapeutic aspiration of their effusion for breathlessness relief.

1. **Phase 1:** Observational cohort study of 200 patients in 5 hospitals for initial data to identify baseline characteristics associated with rate of pleural fluid accumulation and develop a predictive score;
2. **Phase 2:** validation observational cohort study of 40 patients in the same 5 hospitals to validate the score: this will be done in parallel with the analysis of data from phase 1.

If the above 2 phases are successful, we will proceed to:

3. **Phase 3:** A final observational cohort study of 200 patients in the same 5 hospital using the score to demonstrate impact on breathlessness, emergency admissions, number of pleural procedures, quality of life and health economic outcomes: this final phase will be funded separately.

This protocol is for the first and second phases of this study.

7. PARTICIPANT IDENTIFICATION

7.1. Study Participants

Patients with a pleural effusion attending the pleural clinic at 5 UK hospitals for a therapeutic aspiration of their effusion with known or suspected malignant pleural effusion.

7.2. Inclusion Criteria

- Participant is willing and able to give informed consent for participation in the study.
- Aged 18 years or above.
- Diagnosed with pleural effusion on CT or US.
- Patient attending for therapeutic aspiration (large volume drainage) of their pleural effusion: there is no specific minimal pleural fluid volume but this should be larger than required for diagnosis alone (typically 60ml is taken for diagnostic purposes).
- Known or suspected malignancy as the underlying cause of the effusion.
- In the Investigator's opinion, is able and willing to comply with all study requirements.



7.3. Exclusion Criteria

The participant may not enter the study if ANY of the following apply:

- Patients who are pregnant or lactating.
- Pleural infection or other condition requiring admission and chest drain insertion.
- Known transudative pleural effusion or pleural effusion clinically thought to be primarily due to cardiac, renal or hepatic impairment.

8. PROTOCOL PROCEDURES

See appendix for study flow chart

8.1. Recruitment

All patients attending the Pleural Clinic for a therapeutic aspiration of pleural fluid will be informed of the study when their appointment is booked and will receive a patient information leaflet (PIL) by post with their appointment letter. Those who are interested in participating will be asked to contact the study team to confirm that they wish to take part. If no response is received, patients will be approached prior to their fluid drainage procedure by a member of the study team to confirm if they wish to participate, either by telephone or when they attend pleural clinic.

8.2. Screening and Eligibility Assessment

Patients attending the Pleural Clinic for therapeutic aspiration will be screened by confirming they fulfil the inclusion criteria, able to attend the follow up appointment in 1 week and are willing and able to give informed consent. Patients will already have had clinical information, blood tests, thoracic ultrasound and pre-procedure chest X-ray performed as part of standard clinical care.

8.3. Informed Consent

Patients interested in participating in the study will be consented by a member of the study team prior to their drainage procedure, either by telephone or at the time of attending pleural clinic. Written and verbal versions of the Participant Information and Informed Consent will be presented to the participants detailing the exact nature of the study; what it will involve for the participant; and the implications and constraints of the protocol. It will be clearly stated that the participant is free to withdraw from the study at any time for any reason without prejudice to future care, without affecting their legal rights and with no obligation to give the reason for withdrawal.

The participant will be allowed as much time as wished to consider the information, and the opportunity to question the Investigator, their GP or other independent parties to decide whether they will participate in the study. However, there is no minimum time for this.

The participant must personally sign and date the latest approved version of the Informed Consent form before any study specific procedures are performed. The person who obtained consent must be trained in



Good Clinical Practice and have been authorised to do so by the Chief/Principal Investigator and must sign and date the informed consent form.

We anticipate that participants may lose capacity during the study due to disease progression. On the consent form, participants will be asked if they are happy for the study team to retain and use the study data and samples collected up to that point.

8.4. Baseline Assessments

The following baseline assessments will be made:

- Clinical characteristics: duration of symptoms; Eastern Co-operative Oncology Group performance status (ECOG PS); underlying diagnosis, current treatment of effusion e.g. chemotherapy for cancer, presence or absence of contralateral effusion.
- Baseline visual analogue scale for dyspnoea (VASD)
- Blood samples will be taken and stored (optional long term storage for future analysis - in selected sites depending on resources available).
- Baseline QoL questionnaire (EQ-5D 5L)

Patients will then undergo therapeutic aspiration, according to the standard operating procedure. Pleural manometry may be performed during aspiration using bespoke equipment with a manometer integrated in the therapeutic aspiration sheath (supplied by Rocket Medical, optional substudy of 20 patients in Norwich only).

Pleural fluid will be sent to local laboratory for:

- Microscopy and culture, cytology, TP, LDH, pH and glucose. These samples are all part of standard clinical care.

In addition, pleural fluid samples may be stored locally (optional long term storage for future analysis - in selected sites depending on resources available).

Participants will then have a post procedure CXR (as standard care) and thoracic ultrasound (as a study procedure) to assess size of residual effusion and presence of trapped lung, which will be recorded on the Case Report Forms (for later subgroup analysis).

Following discharge, they will complete the 7 day visual analogue scale for dyspnoea questionnaire (7DVQ) over 1 week on paper: this is a 7 day questionnaire in which patients assess their average level of breathlessness on a visual analogue scale daily.

8.5. Follow up visits



- **Day 7:** follow up visit 7 days after the therapeutic aspiration (can be done 5-10 days). This is part of standard clinical care for patients to receive results of pleural fluid testing and decide a management plan. Patients standardly have a CXR at this visit and this will be used to reassess size of effusion. At the point, the 7DVQ will be collected and a CRF completed, particularly to assess whether participants have required further pleural fluid drainage or attended the hospital with breathlessness during the 7 day period. During this period the participant is permitted to have any clinically required intervention.
- **Second pleural procedure:** This will be performed if clinically indicated for diagnostic or symptomatic reasons. Indications for symptomatic drainage are: symptomatic benefit from initial pleural fluid drainage; significant breathlessness; and significant pleural effusion (defined as at least 25% of the hemithorax on CXR or estimated volume of pleural fluid of at least 500ml using ultrasound). Participants will undergo a further pleural drainage (via thoracoscopy, chest drain or indwelling pleural catheter insertion according to clinical requirement in their individual care pathway). Patients will undergo CXR and US at this visit prior to intervention and complete a VASD.
- **Day 30:** Follow up by telephone/review of hospital records to determine further pleural procedures, emergency hospital attendances, other treatment for effusion e.g. chemotherapy, surgery, diuretics
- **3 month:** Follow up by telephone/review of hospital records to determine further pleural procedures, emergency hospital attendances, other treatment for effusion e.g. chemotherapy, surgery, diuretics. We will also collect health related quality of life data using the EQ-5D 5L questionnaire by telephone.

Research staff will informally assess capacity at each follow up visit. If the investigator believes that the participant has lost capacity to consent, no further data will be collected and they will be withdrawn. The study data and samples will be used/retained if the participant had consented for this during the initial consent process.

8.6. Pleural fluid and blood Sample Handling (optional long term storage)

Pleural fluid and blood samples will be processed after taking and centrifuged according to the study specific procedures. They will then be stored locally in a freezer at -80 degrees Celsius. Samples will be stored and may be used for exploratory analysis such as proteomics analysis and measurement of individual biomarkers.

8.7. Discontinuation/Withdrawal of Participants from Study

Each participant has the right to withdraw from the study at any time. In addition, the Investigator may discontinue a participant from the study at any time if the Investigator considers it necessary for any reason including:

- Identification of exclusion criteria e.g. pleural infection
- Inability to perform therapeutic aspiration
- Pregnancy
- Significant protocol deviation



- Withdrawal of Consent
- Loss to follow up

If provided, the reason for withdrawal will be recorded in the CRF. Data and samples collected prior to withdrawal will be included in analysis unless the participant requests they are not used. If the participant loses capacity and they had not consented for their study data/samples to be retained following loss of capacity to consent, their data/samples will not be used.

8.8. Definition of End of Study

The end of study is the date when all sample analysis is complete.

9. DISTRESS PROTOCOL

We recognise that patients attending the Pleural Clinic may find the experience distressing, due to anxiety over the possible cause of their pleural effusion or having to undergo an invasive procedure. They may become distressed during trial procedures, and it is imperative that the researcher responds to this distress in a sensitive and reassuring manner.

The distress protocol is as follows:

1. A participant indicates that they are experiencing a high level of stress or emotional distress OR exhibits behaviours suggesting the trial procedures are too stressful e.g. uncontrolled crying, shaking etc.
2. Stop the trial procedures. One of the researchers or clinical team will offer immediate support by reassuring the patient and exploring the reason for their distress.
3. If the participant feels able to carry on, then trial procedures can be continued. It is important that the participant is aware they can withdraw from the trial at any point.
4. If the participant feels unable to carry on, then stop trial procedures and continue to reassure them. Remind them of the support that is available to them during this process e.g. from the specialist nursing team.
5. If the participant requests to withdraw from the study, then their wishes will be respected.

10. STATISTICS AND DATA ANALYSIS

10.1. Description of Statistical Methods

Reporting will include the number of patients screened for inclusion, the number of participants completing the study and exploratory analysis of any correlations between baseline factors and change in size of effusion on CXR.

10.2. Sample size and analysis plan



Based on our feasibility data, we estimate we need to recruit 200 patients to have complete data available on 150 patients. The main reason for this is that approximately 20% of patients will turn out not to have malignant pleural effusion and therefore will not be eligible for inclusion in the final analysis. The primary outcome measure is at 1 week and is part of standard clinical care and therefore we anticipate that loss to follow up, withdrawal rates and missing data will be minimal based on our feasibility data and previous trial experience. A further validation cohort of 40 patients will be recruited subsequently. Follow up will be either by review of available medical records, telephone or clinical appointment (if patient is coming up to hospital anyway) at 30 days and 3 months.

A sample size of 150 participants would allow us to have a shrinkage factor of 0.95, which is above the recommended 0.9, assuming an R-squared of 0.5 and 8 parameters in the model. It would also allow the estimated R-squared to be within recommended limits of 0.05 of the true R-squared. It would allow the estimation of residual standard deviation to within 13%. Although this is above the recommended 10% we believe that it is still clinically meaningful. It also allows the estimation of the mean outcome to within $\pm 1.5\%$ which is sufficiently precise to be clinically useful, assuming an overall mean of 14 and a sd of 13. This represents 18.75 individuals per variable, which is within the traditional 10-20 individuals per variable rule-of-thumb. The analysis will be based on traditional regression methods and follow the TRIPOD statement. An outline analysis of the analysis is:

1. Initial screening of potential predictor variables to ensure that there is sufficient variation in them and that they are not missing at an unreasonably high level. For example, if a categorical variable does not have $>5\%$ of participants in any category; or if a continuous variable does not cover a broad enough range; After the initial screening, if appropriate data reduction techniques such as principle component analysis will be undertaken to reduce the number of variables to a reasonable amount.
2. Model selection will then be undertaken using variable selection such as backwards elimination. Continuous covariates will be checked for non-linear relationships using splines.
3. Once an appropriate model has been selected, the optimism and internal validation will be estimated using a non-parametric bootstrap approach. If overfitting is found to be an issue, then penalised regression (Lasso or Ridge regression) will be used to reduce the amount of overfitting.
4. Once the final prediction model has been estimated its properties such as discrimination by the estimation of the R^2 and calibration by plotting the observed outcome against the predicted outcome will be explored. If there is a large number of participants excluded due to missing predictor variables then the sensitivity of the final prediction model to missing data will be assessed using multiple imputation.

10.3. Procedure for Accounting for Missing, Unused, and Spurious Data.

Rates of missing data will be reported. For the purposes of this exploratory study, if a patient is “lost to follow up” or dies before the 3 month outcome point, it will be assumed (unless hospital records indicate otherwise) that no further pleural procedure has occurred.

10.4. Inclusion in Analysis

All participants with available data will be included in the day 7 analysis. For the 1 month and 3 month outcomes, all participants including those lost to follow up or who die within the time period will be included in analysis.



10.5. Assessment of effusion size on chest X-ray

Percentage opacification of the hemithorax by effusion will be measured on the post-procedure and follow-up chest X-ray. This is a validated measure of effusion size performed using freely available software (PaintShop Pro, Coral Corporation and ImageJ, National Institute of Health). Anonymised digital chest X-ray images will be uploaded onto the study database. PaintShop Pro is used to outline the hemithorax and effusion. These shapes are then converted into a pixel count by ImageJ. Percentage opacification is calculated by dividing the effusion pixel count by the hemithorax pixel count. This analysis takes approximately 5 minutes per image.

11. DATA MANAGEMENT

11.1. Source Data

Source documents are where data are first recorded, and from which participants' CRF data are obtained. These include, but are not limited to, hospital records (from which medical history and previous and concurrent medication may be summarised into the CRF), clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence.

CRF entries will be considered source data if the CRF is the site of the original recording (e.g. there is no other written or electronic record of data). All documents will be stored safely in confidential conditions. On all study-specific documents, other than the signed consent, the participant will be referred to by the study participant number/code, not by name.

11.2. Access to Data

Direct access will be granted to authorised representatives from the Sponsor, host institution and the regulatory authorities to permit study-related monitoring, audits and inspections.

11.3. Data Recording and Record Keeping

All study data will be entered on to a web-based data management system (REDCap).

The study database is bespoke and hosted on the University of Oxford server with services provided through Oxford University Medical Sciences Division IT Services. The server and database are protected by a number of measures including anti-virus and anti-spyware applications, firewalls, encryption technology and permissions. The database will be backed up on a daily basis. The Data Manager will maintain a list of personnel with authorization to edit and/or view data. All study data will be archived for 5 years.

The database and access to computers are password protected. Paper-based identifiable data at each site will be kept in a locked cabinet, in a locked or ID-access controlled area this will be kept for 6-12 months post the end of the study only if the participant consents to being informed of the study results. If participants do not consent to this, identifiable information will be destroyed once data analysis has taken place.



The participants will be identified by a unique trial specific number in any database. The name and any other identifying detail will NOT be included in any study data electronic file.

12. QUALITY ASSURANCE PROCEDURES

The study will be conducted in accordance with the current approved protocol, principles of GCP, relevant regulations and standard operating procedures. The Trial Management Committee (consisting of the trial manager and chief investigator) will meet monthly to ensure the trial is running as planned.

Regular monitoring will be performed according to principles of GCP. Data will be evaluated for compliance with the protocol and accuracy in relation to source documents. Following written standard operating procedures, the monitors will verify that the clinical study is conducted and data are generated, documented and reported in compliance with the protocol, principles of GCP and the applicable regulatory requirements.

13. ETHICAL AND REGULATORY CONSIDERATIONS

13.1. Declaration of Helsinki

The Investigator will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki.

13.2. Guidelines for Good Clinical Practice

The Investigator will ensure that this study is conducted in accordance with relevant regulations and principles with Good Clinical Practice.

13.3. Approvals

The protocol, informed consent form and participant information sheet have been submitted to an appropriate Research Ethics Committee (REC), for written approval.

The Investigator will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents.

13.4. Reporting

The CI shall submit once a year throughout the clinical study, or on request, an Annual Progress Report to the REC, host organisation and Sponsor. In addition, an End of Study notification and final report will be submitted to the REC, host organisation and Sponsor.

13.5. Participant Confidentiality



The study staff will ensure that the participants' anonymity is maintained. The participants will be identified only by a participant ID number on all study documents and any electronic database, with the exception of the CRF, where participant initials may be added. All documents will be stored securely and only accessible by study staff and authorised personnel. The study will comply with the Data Protection Act, which requires data to be anonymised as soon as it is practical to do so.

13.6. Expenses and Benefits

All visits are part of standard clinical care so no travel expenses will be offered to patients.

14. CORONAVIRUS-19 RISK MITIGATION

In the light of the current COVID-19 pandemic, it is essential that research participants and staff are kept safe and not exposed to any unnecessary risk. The participants eligible for enrolment into REPEAT are a high risk group, because they may have disseminated cancer (albeit undiagnosed at the time of recruitment). REPEAT has been designed to align with standard clinical care. The participant will have two face to face hospital visits, one for initial pleural fluid drainage and the second for results and reassessment. Both are essential visits. All other follow up visits can be done by telephone. All staff and participants will wear masks, practice social distancing where possible and perform good hand hygiene, all as standard care. Therefore the participants or staff will not be exposed to any increased risk of COVID-19 infection while participating in REPEAT.

A further risk from COVID-19 is to the recruitment success of the trial. Recruitment will start in the second quarter of 2021, by which time we anticipate coming to the end of the predicted Winter peak of COVID-19 infections. Therapeutic aspiration is an essential, emergency procedure which prevents hospital admission. Therefore, Pleural Clinics have continued to provide this procedure during the COVID-19 pandemic, and we anticipate this will continue. Therefore we do not predict a decrease in pleural procedures due to COVID-19.

Finally, there is the risk of lack of availability of research staff to support recruitment and data collection. However, the recruiting centres all integrate their research and clinical teams and we anticipate that we will be able to recruit successfully.

15. FINANCE AND INSURANCE

15.1. Funding

This study is funded by a National Institute for Health Research - Research for Patient Benefit grant.

15.2. Insurance

NHS bodies are legally liable for the negligent acts and omissions of their employees. If subjects are harmed whilst taking part in a clinical study as a result of negligence on the part of a member of the study team this liability cover would apply.




Non-negligent harm is not covered by the NHS indemnity scheme. The Norfolk and Norwich University Hospital NHS Foundation Trust, therefore, cannot agree in advance to pay compensation in these circumstances.

In exceptional circumstances an ex-gratia payment may be offered.

16. PUBLICATION POLICY

Once completed, this study will be submitted to a conference as an abstract and as a paper to a peer-reviewed journal.

17. APPENDIX 1: Study Flow chart



18. REFERENCES

- 1 Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, Davies CW, Grayez J, Harrison R, Prasad A, Crosthwaite N, Lee YC, Davies RJ, Miller RF, Rahman NM. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. *JAMA*. 2012; **307**: 2383-9.
- 2 Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. *Chest*. 2005; **128**: 1431-5.
- 3 Markov AG, Amasheh S. Tight junction physiology of pleural mesothelium. *Front Physiol*. 2014; **5**: 221.
- 4 Spella M, Giannou AD, Stathopoulos GT. Switching off malignant pleural effusion formation-fantasy or future? *J Thorac Dis*. 2015; **7**: 1009-20.
- 5 Fafliora E, Hatzoglou C, Gourgoulialis KI, Zarogiannis SG. Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. *Physiol Rep*. 2016; **4**.
- 6 Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. *Thorax*. 2010; **65**: ii32-40.
- 7 Numico G, Cristofano A, Mozzicafreddo A, Cursio OE, Franco P, Courthod G, Trogu A, Malossi A, Cucchi M, Sirotova Z, Alvaro MR, Stella A, Grasso F, Spinazze S, Silvestris N. Hospital admission of cancer patients: avoidable practice or necessary care? *PLoS One*. 2015; **10**: e0120827.
- 8 Hjermland MJ, Kolflaath J, Lokken AO, Hanssen SB, Normann AP, Aass N. Are emergency admissions in palliative cancer care always necessary? Results from a descriptive study. *BMJ Open*. 2013; **3**.
- 9 Yates M, Barrett A. Oncological emergency admissions to the Norfolk and Norwich University Hospital: an audit of current arrangements and patient satisfaction. *Clin Oncol (R Coll Radiol)*. 2009; **21**: 226-33.
- 10 Grosu HB, Molina S, Casal R, Song J, Li L, Diaz-Mendoza J, Reddy C, Yarmus L, Schiavo D, Simoff M, Johnston J, Raid AA, Feller-Kopman D, Lee H, Sahetya S, Foley F, Maldonado F, Tian X, Noor L, Miller R, Mudambi L, Saettele T, Vial-Rodriguez M, Eapen GA, Ost DE. Risk factors for pleural effusion recurrence in patients with malignancy. *Respirology*. 2019; **24**: 76-82.
- 11 Boshuizen RC, Vincent AD, van den Heuvel MM. Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion. *Support Care Cancer*. 2013; **21**: 3109-16.
- 12 Rahman NM, Pepperell J, Rehal S, Saba T, Tang A, Ali N, West A, Hettiarachchi G, Mukherjee D, Samuel J, Bentley A, Dowson L, Miles J, Ryan CF, Yoneda KY, Chauhan A, Corcoran JP, Psallidas I, Wrightson JM, Hallifax R, Davies HE, Lee YC, Dobson M, Hedley EL, Seaton D, Russell N, Chapman M, McFadyen BM, Shaw RA, Davies RJ, Maskell NA, Nunn AJ, Miller RF. Effect of Opioids vs NSAIDs and



Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. JAMA. 2015; **314**: 2641-53.

